ClinicalTrials.gg
RecruitingNCT07691970ROSY-SUpdated Nov 10, 2026

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

A Phase 3 interventional study of Anifrolumab and Anifrolumab in Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus, sponsored by AstraZeneca. Recruiting at 166 sites in 35 countries. Open to participants aged 5 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 10, 2026Now RecruitingFirst sites in 13 new countries+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,072
Allocation
Non-randomized
Ages
5 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Planned enrollment
Largest of 20
1,072 · median 159
Started
2026
with 5 others
Phase 3
9 of 20
4 open now
Primary completion
2032-12
later than 10 of 10 live
Registered
17th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one has the largest planned enrollment, is one of 6 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 17th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability.

Study details include:

  • Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study.
  • The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study.
  • The participants will continue to receive anifrolumab the same way they received it in the parent trial
  • A participant is considered to have completed the study when they meet one of the discontinuation criteria.
  • Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.
03

Conditions studied

  • Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
5 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:

    1 Participants must have completed the entirety of the parent study and should have received at least one dose of anifrolumab in the parent study.

  • In the opinion of the Investigator, the potential benefit to the participant of continuing anifrolumab at the end of the parent study outweighs the risk.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Participants should continue following the contraception requirements as per Appendix B from study enrolment up to 16 weeks after the last dose of study treatment.
  • Capable of giving signed described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Capable of adhering to the treatment plan related to this ROSY-S study.

Exclusion criteria

Exclusion Criteria:

  • Participant develops to any of the components of anifrolumab.
  • Female participant who is breastfeeding, pregnant, or intends to become pregnant during participation in this study.
  • Currently participating in any study or participated in an investigational study within 30 days prior to enrolment or within 5 half-lives of the investigational medicinal product (other than the parent study for anifrolumab) whichever is longer.
  • Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting anifrolumab.
  • Currently receiving or have received prohibited medication(s) as specified in parent protocols prior to signing ICF.
  • Participants who are planning to use live/.
  • Participants who are planning to use any other therapies, including B-cell therapies, that in the opinion of the Investigator could jeopardize or would compromise the participant's ability to participate in the program as determined by the Investigator.
  • Participants with any medical condition (such as cancer or viral infections [hepatitis]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
  • Participants who discontinued the parent study prior to completion of all study visits.
  • Local access to approved and commercially available (reimbursed) drug for the defined indication as permitted by local/country regulation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,072 participants (estimated)

Study arms

  • Experimental
    Anifrolumab

    This is a single arm open-label study with the primary objective of providing continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment and assessing long-term safety and tolerability of anifrolumab until participant meets one of the study discontinuation criteria.

    Combination Product: Anifrolumab · Drug: Anifrolumab

Interventions

  • Combination productAnifrolumab

    Anifrolumab pre-filled syringe

  • Combination productAnifrolumab

    Anifrolumab solution for injection in pre-filled pen

  • Anifrolumab concentrate for solution for infusion

06

What researchers measure

Primary outcomes

  1. SAEs and Non-Serious AEs

    Safety will be evaluated by monitoring and assessing SAEs and Non-Serious AEs as reported throughout the study and until 12 weeks after the last dose of anifrolumab

    Time frame: From first dose administered and until 12 weeks after the last dose of Anifrolumab

07

Study locations

4 of 166 sites recruiting
  • Research Site
    Phoenix, Arizona 85028, United States
    Not yet recruiting
  • Research Site
    Irvine, California 92617, United States
    Not yet recruiting
  • Research Site
    Los Angeles, California 90045, United States
    Recruiting
  • Research Site
    San Francisco, California 94115, United States
    Not yet recruiting
  • Research Site
    Boca Raton, Florida 33486, United States
    Recruiting
  • Research Site
    Fort Lauderdale, Florida 33309, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Not yet recruiting
  • Research Site
    Indianapolis, Indiana 46202, United States
    Not yet recruiting
  • Research Site
    Baltimore, Maryland 21287, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02115, United States
    Not yet recruiting
  • Research Site
    Ann Arbor, Michigan 48109, United States
    Not yet recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Not yet recruiting
  • Research Site
    Omaha, Nebraska 68114, United States
    Not yet recruiting
  • Research Site
    New York, New York 10029, United States
    Not yet recruiting
  • Research Site
    Charlotte, North Carolina 28207, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Columbus, Ohio 43230, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Research Site
    Charleston, South Carolina 29425, United States
    Not yet recruiting
  • Research Site
    Dallas, Texas 75390-8843, United States
    Not yet recruiting
  • Research Site
    Roanoke, Virginia 24016, United States
    Not yet recruiting
  • Research Site
    Quilmes, 1878, Argentina
    Not yet recruiting
  • Research Site
    San Miguel, 1663, Argentina
    Not yet recruiting
  • Research Site
    Melbourne, 3004, Australia
    Not yet recruiting
  • Research Site
    Mitcham, 3132, Australia
    Not yet recruiting
  • Research Site
    Westmead, 2145, Australia
    Not yet recruiting
  • Research Site
    Graz, 8010, Austria
    Not yet recruiting
  • Research Site
    Graz, 8036, Austria
    Not yet recruiting
  • Research Site
    Linz, 4020, Austria
    Not yet recruiting
  • Research Site
    Vienna, 1130, Austria
    Not yet recruiting
  • Research Site
    Ghent, 9000, Belgium
    Not yet recruiting
  • Research Site
    Leuven, 3000, Belgium
    Not yet recruiting
  • Research Site
    Belo Horizonte, 30150-221, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90035-903, Brazil
    Not yet recruiting
  • Research Site
    Rio de Janeiro, 22470-220, Brazil
    Not yet recruiting
  • Research Site
    Salvador, 40150-150, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 05403-000, Brazil
    Not yet recruiting
  • Research Site
    Haskovo, 6304, Bulgaria
    Not yet recruiting
  • Research Site
    Plovdiv, 4001, Bulgaria
    Not yet recruiting
  • Research Site
    Sofia, 1463, Bulgaria
    Not yet recruiting
  • Research Site
    Sofia, 1618, Bulgaria
    Not yet recruiting
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
    Not yet recruiting
  • Research Site
    Québec, G1V 3M7, Canada
    Not yet recruiting
  • Research Site
    Santiago, 7500571, Chile
    Not yet recruiting
  • Research Site
    Beijing, 100191, China
    Not yet recruiting
  • Research Site
    Chongqing, 400010, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510080, China
    Not yet recruiting
  • Research Site
    Jinan, 250022, China
    Not yet recruiting
  • Research Site
    Lanzhou, 730000, China
    Not yet recruiting
  • Research Site
    Shanghai, 200001, China
    Not yet recruiting
  • Research Site
    Shenzhen, 518020, China
    Not yet recruiting
  • Research Site
    Shenzhen, 518053, China
    Not yet recruiting
  • Research Site
    Bogotá, 110221, Colombia
    Not yet recruiting
  • Research Site
    Prague, 12850, Czechia
    Not yet recruiting
  • Research Site
    Bordeaux, 33076, France
    Not yet recruiting
  • Research Site
    Nantes, 44093, France
    Not yet recruiting
  • Research Site
    Paris, 75010, France
    Not yet recruiting
  • Research Site
    Paris, 75014, France
    Not yet recruiting
  • Research Site
    Paris, 75020, France
    Not yet recruiting
  • Research Site
    Poitiers, 86000, France
    Not yet recruiting
  • Research Site
    Rennes, 35033, France
    Not yet recruiting
  • Research Site
    Strasbourg, 67200, France
    Not yet recruiting
  • Research Site
    Toulouse, 31059, France
    Not yet recruiting
  • Research Site
    Toulouse, 31300, France
    Not yet recruiting
  • Research Site
    Berlin, 13353, Germany
    Not yet recruiting
  • Research Site
    Dresden, 1309, Germany
    Not yet recruiting
  • Research Site
    Essen, 45122, Germany
    Not yet recruiting
  • Research Site
    Freiburg im Breisgau, 79104, Germany
    Not yet recruiting
  • Research Site
    Freiburg im Breisgau, 79106, Germany
    Not yet recruiting
  • Research Site
    Hanover, 30625, Germany
    Not yet recruiting
  • Research Site
    Kiel, 24105, Germany
    Not yet recruiting
  • Research Site
    Mainz, 55131, Germany
    Not yet recruiting
  • Research Site
    Marburg, 35043, Germany
    Not yet recruiting
  • Research Site
    Münster, 48149, Germany
    Not yet recruiting
  • Research Site
    Regensburg, 93053, Germany
    Not yet recruiting
  • Research Site
    Tübingen, 72076, Germany
    Not yet recruiting
  • Research Site
    Wuppertal, 42283, Germany
    Not yet recruiting
  • Research Site
    Chaïdári, 124 62, Greece
    Not yet recruiting
  • Research Site
    Hyderabad, 500082, India
    Not yet recruiting
  • Research Site
    Kolkata, 700020, India
    Not yet recruiting
  • Research Site
    New Delhi, 110060, India
    Not yet recruiting
  • Research Site
    Pune, 411001, India
    Not yet recruiting
  • Research Site
    Haifa, 31048, Israel
    Not yet recruiting
  • Research Site
    Kfar Saba, 4428164, Israel
    Not yet recruiting
  • Research Site
    Brescia, 25123, Italy
    Not yet recruiting
  • Research Site
    Catania, 95123, Italy
    Not yet recruiting
  • Research Site
    Cona, 44124, Italy
    Not yet recruiting
  • Research Site
    Florence, 50121, Italy
    Not yet recruiting
  • Research Site
    Milan, 20122, Italy
    Not yet recruiting
  • Research Site
    Milan, 20132, Italy
    Not yet recruiting
  • Research Site
    Naples, 80131, Italy
    Not yet recruiting
  • Research Site
    Pavia, 27100, Italy
    Not yet recruiting
  • Research Site
    Roma, 00144, Italy
    Not yet recruiting
  • Research Site
    Roma, 00168, Italy
    Not yet recruiting
  • Research Site
    Fukuoka, 812-8582, Japan
    Not yet recruiting
  • Research Site
    Kanazawa, 920-8641, Japan
    Not yet recruiting
  • Research Site
    Maebashi, 371-8511, Japan
    Not yet recruiting
  • Research Site
    Nagoya, 467-8602, Japan
    Not yet recruiting
  • Research Site
    Sapporo, 060-8648, Japan
    Not yet recruiting
  • Research Site
    Yokohama, 236-0004, Japan
    Not yet recruiting

Showing the first 100 of 166 sites across 35 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment. "Yes" indicates that AstraZeneca is accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability commitments in line with EFPIA/PhRMA Data Sharing Principles. For details of timelines, refer to AstraZeneca's disclosure commitment.

Access criteria: When a request has been approved, AstraZeneca will provide access to anonymized individual patient-level data via a secure research environment (Vivli). A signed Data Usage Agreement must be in place before accessing the data.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2032, 75 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 75 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 9, 2026
StartActual
Aug 31, 2026was Sep 2026
Primary completionEst.
Dec 30, 2032
CompletionEst.
Dec 30, 2032
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
126 sites added, 1 site removed — first sites in Argentina, Australia, Canada, Chile, China and 8 more
All 13 countries

Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Germany, Mexico, Netherlands, Portugal, South Africa, Vietnam

. 41 sites changed recruiting status (37 now not yet recruiting, 4 now recruiting)
Show 41 sites
  • Research Site · Los Angeles, United Statesno status→Recruiting
  • Research Site · Fort Lauderdale, United Statesno status→Recruiting
  • Research Site · Chicago, United Statesno status→Not yet recruiting
  • Research Site · Ann Arbor, United Statesno status→Not yet recruiting
  • Research Site · New York, United Statesno status→Not yet recruiting
  • Research Site · Charleston, United Statesno status→Not yet recruiting
  • Research Site · Graz, Austriano status→Not yet recruiting
  • Research Site · Ghent, Belgiumno status→Not yet recruiting
  • Research Site · Salvador, Brazilno status→Not yet recruiting
  • Research Site · Sofia, Bulgariano status→Not yet recruiting
  • Research Site · Bordeaux, Franceno status→Not yet recruiting
  • Research Site · Strasbourg, Franceno status→Not yet recruiting
  • Research Site · Toulouse, Franceno status→Not yet recruiting
  • Research Site · Chaïdári, Greeceno status→Not yet recruiting
  • Research Site · Kolkata, Indiano status→Not yet recruiting
  • Research Site · Haifa, Israelno status→Not yet recruiting
  • Research Site · Milan, Italyno status→Not yet recruiting
  • Research Site · Sapporo, Japanno status→Not yet recruiting
  • Research Site · Iloilo City, Philippinesno status→Not yet recruiting
  • Research Site · Lipa City, Philippinesno status→Not yet recruiting
  • Research Site · Bydgoszcz, Polandno status→Not yet recruiting
  • Research Site · Kielce, Polandno status→Not yet recruiting
  • Research Site · Krakow, Polandno status→Not yet recruiting
  • Research Site · Iași, Romaniano status→Not yet recruiting
  • Research Site · Kragujevac, Serbiano status→Not yet recruiting
  • Research Site · Piešťany, Slovakiano status→Not yet recruiting
  • Research Site · Seoul, South Koreano status→Not yet recruiting
  • Research Site · Barcelona, Spainno status→Not yet recruiting
  • Research Site · Granada, Spainno status→Not yet recruiting
  • Research Site · Madrid, Spainno status→Not yet recruiting
  • …and 11 more on the registry record
Show 126 added (15 United States, 13 Germany, 9 Italy, 9 Spain, 8 China, 7 France, 5 Brazil, 5 Japan, 5 Mexico, 5 Poland, 4 South Korea, 3 Australia, 3 Bulgaria, 3 India, 3 Portugal, 3 Taiwan, 3 Thailand, 3 United Kingdom, 2 Argentina, 2 Austria, 2 Canada, 2 Romania, 1 Chile, 1 Colombia, 1 Czechia, 1 Israel, 1 Netherlands, 1 Philippines, 1 Serbia, 1 Slovakia, 1 South Africa, 1 Vietnam, 1 Belgium, 1 Turkey (Türkiye))
  • Research Site · Phoenix, United States
  • Research Site · San Francisco, United States
  • Research Site · Boca Raton, United States
  • Research Site · Rochester, United States
  • Research Site · Omaha, United States
  • Research Site · Charlotte, United States
  • Research Site · Cleveland, United States
  • Research Site · Portland, United States
  • Research Site · Roanoke, United States
  • Research Site · Quilmes, Argentina
  • Research Site · San Miguel, Argentina
  • Research Site · Melbourne, Australia
  • Research Site · Mitcham, Australia
  • Research Site · Linz, Austria
  • Research Site · Vienna, Austria
  • Research Site · Rio de Janeiro, Brazil
  • Research Site · Santa Efigênia, Brazil
  • Research Site · São Paulo, Brazil
  • Research Site · Plovdiv, Bulgaria
  • Research Site · Sofia, Bulgaria
  • Research Site · Québec, Canada
  • Research Site · Santiago, Chile
  • Research Site · Beijing, China
  • Research Site · Chongqing, China
  • Research Site · Guangzhou, China
  • Research Site · Jinan, China
  • Research Site · Lanzhou, China
  • Research Site · Shanghai, China
  • Research Site · Shenzhen, China
  • Research Site · Shenzhen, China
  • …and 96 more on the registry record
Show 1 removed
  • Research Site · Santa Efigênia, Brazil
across 3 updates, Oct 2, 2026 – Nov 10, 2026
Start date
Sep 1, 2026→Aug 31, 2026 (actual)
Oct 2, 2026
Primary completion
Dec 31, 2032→Dec 30, 2032
Oct 2, 2026
Study completion
Dec 31, 2032→Dec 30, 2032
Oct 2, 2026
Show all 3 updates
  1. Nov 10, 2026
    13 sites added
    Show 13 added (3 United States, 2 Spain, 1 Australia, 1 Brazil, 1 Bulgaria, 1 Canada, 1 Italy, 1 Mexico, 1 South Korea, 1 Taiwan)
    • Research Site · Irvine, United States
    • Research Site · Baltimore, United States
    • Research Site · Boston, United States
    • Research Site · Westmead, Australia
    • Research Site · Porto Alegre, Brazil
    • Research Site · Haskovo, Bulgaria
    • Research Site · Toronto, Canada
    • Research Site · Naples, Italy
    • Research Site · México, Mexico
    • Research Site · Seoul, South Korea
    • Research Site · Barcelona, Spain
    • Research Site · Madrid, Spain
    • Research Site · Taichung, Taiwan
    + 1 other change: verification date
  2. Oct 28, 2026
    26 sites added, 1 site removed. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Research Site · Boca Raton, United StatesNot yet recruiting→Recruiting
    • Research Site · Fort Lauderdale, United StatesNot yet recruiting→Recruiting
    • Research Site · Charlotte, United StatesNot yet recruiting→Recruiting
    Show 26 added (7 Germany, 5 France, 3 United States, 2 Italy, 2 Poland, 2 Spain, 1 Belgium, 1 Brazil, 1 Japan, 1 Mexico, 1 Turkey (Türkiye))
    • Research Site · Indianapolis, United States
    • Research Site · Columbus, United States
    • Research Site · Dallas, United States
    • Research Site · Leuven, Belgium
    • Research Site · Belo Horizonte, Brazil
    • Research Site · Nantes, France
    • Research Site · Paris, France
    • Research Site · Poitiers, France
    • Research Site · Rennes, France
    • Research Site · Toulouse, France
    • Research Site · Berlin, Germany
    • Research Site · Freiburg im Breisgau, Germany
    • Research Site · Freiburg im Breisgau, Germany
    • Research Site · Hanover, Germany
    • Research Site · Münster, Germany
    • Research Site · Regensburg, Germany
    • Research Site · Wuppertal, Germany
    • Research Site · Catania, Italy
    • Research Site · Pavia, Italy
    • Research Site · Fukuoka, Japan
    • Research Site · Veracruz, Mexico
    • Research Site · Krakow, Poland
    • Research Site · Lodz, Poland
    • Research Site · A Coruña, Spain
    • Research Site · Valladolid, Spain
    • Research Site · Ümraniye, Turkey (Türkiye)
    Show 1 removed
    • Research Site · Santa Efigênia, Brazil
    + 1 other change: verification date
  3. Oct 2, 2026
    Not yet recruiting→Recruiting
    87 sites added — first sites in Argentina, Australia, Canada, Chile, China and 8 more
    All 13 countries

    Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Germany, Mexico, Netherlands, Portugal, South Africa, Vietnam

    . 41 sites changed recruiting status (40 now not yet recruiting, 1 now recruiting)
    Show 41 sites
    • Research Site · Los Angeles, United Statesno status→Recruiting
    • Research Site · Fort Lauderdale, United Statesno status→Not yet recruiting
    • Research Site · Chicago, United Statesno status→Not yet recruiting
    • Research Site · Ann Arbor, United Statesno status→Not yet recruiting
    • Research Site · New York, United Statesno status→Not yet recruiting
    • Research Site · Charleston, United Statesno status→Not yet recruiting
    • Research Site · Graz, Austriano status→Not yet recruiting
    • Research Site · Graz, Austriano status→Not yet recruiting
    • Research Site · Ghent, Belgiumno status→Not yet recruiting
    • Research Site · Salvador, Brazilno status→Not yet recruiting
    • Research Site · Sofia, Bulgariano status→Not yet recruiting
    • Research Site · Bordeaux, Franceno status→Not yet recruiting
    • Research Site · Strasbourg, Franceno status→Not yet recruiting
    • Research Site · Toulouse, Franceno status→Not yet recruiting
    • Research Site · Chaïdári, Greeceno status→Not yet recruiting
    • Research Site · Kolkata, Indiano status→Not yet recruiting
    • Research Site · Haifa, Israelno status→Not yet recruiting
    • Research Site · Milan, Italyno status→Not yet recruiting
    • Research Site · Sapporo, Japanno status→Not yet recruiting
    • Research Site · Iloilo City, Philippinesno status→Not yet recruiting
    • Research Site · Lipa City, Philippinesno status→Not yet recruiting
    • Research Site · Bydgoszcz, Polandno status→Not yet recruiting
    • Research Site · Kielce, Polandno status→Not yet recruiting
    • Research Site · Krakow, Polandno status→Not yet recruiting
    • Research Site · Iași, Romaniano status→Not yet recruiting
    • Research Site · Kragujevac, Serbiano status→Not yet recruiting
    • Research Site · Piešťany, Slovakiano status→Not yet recruiting
    • Research Site · Seoul, South Koreano status→Not yet recruiting
    • Research Site · Barcelona, Spainno status→Not yet recruiting
    • Research Site · Granada, Spainno status→Not yet recruiting
    • …and 11 more on the registry record
    Show 87 added (9 United States, 8 China, 6 Germany, 6 Italy, 5 Spain, 4 Japan, 3 Brazil, 3 India, 3 Mexico, 3 Poland, 3 Portugal, 3 South Korea, 3 Thailand, 3 United Kingdom, 2 Argentina, 2 Australia, 2 Austria, 2 Bulgaria, 2 France, 2 Romania, 2 Taiwan, 1 Canada, 1 Chile, 1 Colombia, 1 Czechia, 1 Israel, 1 Netherlands, 1 Philippines, 1 Serbia, 1 Slovakia, 1 South Africa, 1 Vietnam)
    • Research Site · Phoenix, United States
    • Research Site · San Francisco, United States
    • Research Site · Boca Raton, United States
    • Research Site · Rochester, United States
    • Research Site · Omaha, United States
    • Research Site · Charlotte, United States
    • Research Site · Cleveland, United States
    • Research Site · Portland, United States
    • Research Site · Roanoke, United States
    • Research Site · Quilmes, Argentina
    • Research Site · San Miguel, Argentina
    • Research Site · Melbourne, Australia
    • Research Site · Mitcham, Australia
    • Research Site · Linz, Austria
    • Research Site · Vienna, Austria
    • Research Site · Rio de Janeiro, Brazil
    • Research Site · Santa Efigênia, Brazil
    • Research Site · São Paulo, Brazil
    • Research Site · Plovdiv, Bulgaria
    • Research Site · Sofia, Bulgaria
    • Research Site · Québec, Canada
    • Research Site · Santiago, Chile
    • Research Site · Beijing, China
    • Research Site · Chongqing, China
    • Research Site · Guangzhou, China
    • Research Site · Jinan, China
    • Research Site · Lanzhou, China
    • Research Site · Shanghai, China
    • Research Site · Shenzhen, China
    • Research Site · Shenzhen, China
    • …and 57 more on the registry record
    Start date Sep 1, 2026→Aug 31, 2026 (now actual)
    Primary completion Dec 31, 2032→Dec 30, 2032
    Study completion Dec 31, 2032→Dec 30, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07691970
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Aug 31, 2026
Primary completion
Dec 30, 2032 (estimated)
Completion
Dec 30, 2032 (estimated)
Last update
Nov 10, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
+1877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion